Author: labstruenorth@gmail.com

Researchers are launching a clinical trial that could open the door to a potential cure for more people living with Chronic Granulomatous Disease (CGD), a rare inherited condition that leaves the immune system vulnerable to serious infections and inflammation. Currently, the only known cure is a bone marrow transplant, but this option has historically been limited to patients lucky enough to have a perfectly matched donor. This new study aims to change that.

The trial is testing whether a haploidentical transplant—using a related donor who is only a partial, or “half,” match—can be performed safely and effectively. To help the body accept these partially matched cells, researchers are using a carefully designed combination of medications, including alemtuzumab, busulfan, total body irradiation, and post-transplant cyclophosphamide. This approach is designed to reduce the risk of complications like graft-versus-host disease while still allowing the donor cells to successfully take hold and rebuild a healthy immune system.

What makes this research especially encouraging is the potential to dramatically widen the pool of eligible donors. Many people with CGD who could benefit from a curative transplant currently have no perfectly matched donor, whether related or unrelated, and are left without this treatment path. If this haploidentical approach proves successful, family members such as parents, siblings, or children—who are far more likely to be partial matches—could step in as donors, offering hope to patients who previously had few options.

The trial, open to participants ages 4 to 65, includes a thorough and carefully monitored process, from pre-transplant screening and preparation to an extended recovery period with regular follow-up visits over several years. This level of careful monitoring reflects the research team’s commitment to patient safety while they gather important data on how well the body accepts the transplant and how effectively it restores immune function.

Efforts like this represent meaningful progress in rare disease research, where expanding treatment access can make a life-changing difference for patients and families. By exploring safer ways to use partially matched donors, this study has the potential to bring a curative option within reach for more people affected by CGD. As with any clinical trial, results will need to be carefully evaluated, but the initiative itself marks an encouraging step forward for the CGD community.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide

A new clinical trial listed on ClinicalTrials.gov is set to investigate two different approaches used to help patients achieve successful spinal fusion after ALIF (anterior lumbar interbody fusion) and XLIF (extreme lateral interbody fusion) procedures. The study will prospectively compare radiographic fusion rates and clinical outcomes between patients treated with ViviGen, a bone graft substitute, and those treated with recombinant human bone morphogenetic protein-2 (rhBMP-2), a widely used growth factor in spinal surgery.

Spinal fusion surgery is commonly performed to stabilize the spine and relieve pain in patients with degenerative disc disease or other spinal conditions. A critical factor in the success of these procedures is whether the vertebrae achieve solid bony fusion over time. Researchers hope this head-to-head comparison, focusing on single-level ALIF at L5/S1 and single-level XLIF at L4/5, will provide clearer evidence about which option offers better fusion outcomes and patient recovery experiences.

Studies like this one are valuable because they give surgeons and patients more concrete data to guide treatment decisions. By directly comparing two established options rather than relying on separate studies conducted under different conditions, the trial design allows for a more direct, apples-to-apples evaluation. This kind of comparative research is an encouraging step toward refining surgical protocols and helping ensure patients receive the most effective option for their individual needs.

If the trial proceeds as designed and produces meaningful results, it could help inform future clinical guidelines around bone grafting choices in spinal fusion surgery, potentially improving fusion success rates and patient outcomes across the field. Continued investment in this type of rigorous, prospective clinical research reflects a broader commitment to advancing evidence-based care in spine surgery.

As with all clinical trials, results will need time to mature and undergo peer review before firm conclusions can be drawn. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Comparison of Radiographic Fusion Rate and Clinical Outcome of ALIF and XLIF Performed With Either Recombinant Human Bone Morphogenetic Protein-2 or ViviGen®

Researchers have launched a clinical trial investigating whether simple oral amino acid supplements, taken during hemodialysis sessions, could help improve quality of life for patients living with end-stage kidney disease (ESKD). The study, registered on ClinicalTrials.gov, will compare the effects of a single essential amino acid—valine—against a broader blend of essential amino acids (EAA) to see which approach best supports patients battling fatigue, frailty, and cognitive fog.

For many people undergoing regular hemodialysis, these three challenges—tiredness, physical weakness, and mental cloudiness—can significantly affect daily life. Nutritional strategies like amino acid supplementation are appealing because they are relatively simple, non-invasive, and can potentially be incorporated directly into existing dialysis routines without major disruption to patient care.

By directly comparing a single amino acid to a more comprehensive essential amino acid formula, the trial aims to generate practical insights: does a targeted, simpler approach work just as well as a broader nutritional strategy, or is the combination formula more effective? Answering this question could help clinicians design more efficient and cost-effective nutrition protocols for dialysis centers in the future.

This kind of research reflects a growing interest in supportive, quality-of-life-focused treatments for chronic kidney disease patients—complementing the core dialysis treatment itself. If the findings show meaningful improvements in energy levels, physical resilience, or mental clarity, it could pave the way for simple, accessible nutritional additions to standard dialysis care that help patients feel more like themselves.

As with all ongoing clinical trials, results will need to be published and peer-reviewed before any conclusions can be drawn about real-world benefits. This article is for informational purposes only and is not medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis

A newly registered clinical trial is taking on an important question for men living with Peyronie’s disease (PD): what options exist for those who didn’t see improvement with standard collagenase clostridium histolyticum (CCH) treatment? The study, listed on ClinicalTrials.gov, is designed to evaluate a novel CCH administration protocol specifically among men previously classified as non-responders to the therapy.

CCH is an FDA-approved enzyme-based treatment used to help break down the collagen buildup responsible for the curvature and plaque associated with Peyronie’s disease. While many patients have benefited from CCH over the years, not everyone responds to the standard protocol, leaving a subset of men searching for further options. This trial’s focus on refining or adjusting the administration approach reflects a thoughtful, patient-centered effort to expand the pool of men who might eventually benefit from this treatment.

The study design includes a comparison between control participants and those receiving the modified protocol, allowing researchers to look closely at key clinical outcomes. This kind of structured, comparative approach is valuable because it can help clarify whether adjustments to dosing, injection technique, or treatment sequencing make a meaningful difference for men who didn’t see results the first time around.

What makes this research particularly encouraging is its focus on a specific, often overlooked group: prior non-responders. Rather than treating a lack of initial response as a dead end, this trial represents an effort to better understand why some men don’t respond and whether tailored protocol changes can help. If successful, this line of research could eventually broaden treatment options and offer renewed hope to men who previously felt they had exhausted their choices with CCH therapy.

As with all ongoing clinical trials, results are still forthcoming, and it will be important to see the full data once the study concludes. Nonetheless, the very existence of this kind of targeted research is a positive sign that the field continues to innovate on behalf of patients. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders

A new clinical trial is underway to investigate whether adding an innovative immunotherapy agent to standard treatment can improve outcomes for patients with hormone receptor-positive, HER2-negative breast cancer who did not respond well to initial chemotherapy. This subgroup of patients often faces limited options after a poor chemotherapy response, making new treatment strategies especially valuable.

The trial will enroll approximately 40 participants whose tumors shrank by less than 40% after two cycles of standard TAC chemotherapy. These participants will be randomly assigned to receive either a combination of an aromatase inhibitor and a CDK4/6 inhibitor—both established therapies for this cancer subtype—or that same combination plus QL1706, a dual-action immunotherapy drug combining iparomlimab and tuvonralimab. Premenopausal and perimenopausal participants will also receive ovarian function suppression to ensure the endocrine therapy is fully effective.

What makes this study particularly encouraging is its focus on precision and adaptability in cancer care. Rather than continuing with a chemotherapy approach that isn’t working well for certain patients, researchers are exploring whether pivoting to a combination of endocrine therapy and immunotherapy could better harness the body’s own immune system to fight the tumor. The trial will track several important measures, including objective response rate, pathological response, changes in the cell-proliferation marker Ki-67, and shifts in the tumor’s immune microenvironment—giving researchers a detailed picture of how the treatment is working on multiple biological levels.

This kind of research reflects a broader and hopeful trend in oncology: using immunotherapy not just as a last resort, but as a strategic addition to established treatments for patients whose cancer shows early signs of chemotherapy resistance. If successful, this approach could offer a meaningful new pathway for patients who currently have fewer options after an underwhelming chemotherapy response, potentially improving their chances of a strong treatment outcome before surgery.

While this trial is just beginning and results will take time, its design represents thoughtful, patient-focused innovation—aiming to match treatment intensity and type to how an individual tumor is actually behaving. As with all clinical trials, outcomes are not yet known, and patients interested in trial participation should discuss options with their oncology care team. This article is for informational purposes only and is not medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy

A new multicenter Phase 2 clinical trial has launched to evaluate a potential new approach for patients battling metastatic colorectal cancer that has progressed after initial treatment. The study, registered on ClinicalTrials.gov, will compare the standard combination of FOLFIRI chemotherapy and bevacizumab against that same regimen with the addition of pelareorep, an investigational therapeutic agent being explored for its potential to enhance anti-tumor activity.

The trial specifically targets patients with RAS-mutated, microsatellite-stable (MSS) metastatic colorectal cancer who have already progressed after one prior line of oxaliplatin-based therapy. This is a particularly challenging patient population, as RAS-mutated and MSS tumors have historically been less responsive to certain newer immune-based treatments, making the search for effective second-line options especially important for both patients and clinicians.

By using a randomized, open-label design, researchers aim to generate clear comparative data on both efficacy and safety between the two treatment arms. This structured approach reflects the kind of rigorous science needed to determine whether adding pelareorep to a well-established chemotherapy backbone can meaningfully improve results for patients facing limited options after their cancer has progressed.

The initiation of this trial is an encouraging sign of continued innovation in the oncology field, particularly for hard-to-treat cancer subtypes. Second-line treatment trials like this one are essential steps in the broader effort to expand the toolkit available to oncologists, and successful outcomes could eventually open the door to new combination therapy options for a patient population that currently has relatively few targeted alternatives.

While it will take time before results are available, the launch of this Phase 2 study represents meaningful progress in cancer research and reflects the ongoing commitment of the research community to improving outcomes for people living with metastatic colorectal cancer. This article is for informational purposes only and is not medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

TearSolutions has announced that its investigational peptide therapy, Lacripep, is moving into a Phase 2 clinical trial for the treatment of neurotrophic keratitis, a rare and potentially vision-threatening condition caused by reduced corneal sensation. The advancement follows the U.S. Food and Drug Administration granting the therapy two separate special designations, underscoring regulatory recognition of its potential to address a significant unmet medical need.

Lacripep is derived from lacritin, a naturally occurring protein found in human tears that plays a role in maintaining a healthy ocular surface. By harnessing a peptide fragment of this natural protein, TearSolutions aims to restore protective tear film function and support corneal healing in patients whose eyes have lost normal sensory feedback due to nerve damage. Neurotrophic keratitis can lead to persistent epithelial defects and, if untreated, more serious complications, making new therapeutic options especially valuable for patients and eye care specialists alike.

The dual FDA designations granted to Lacripep are typically awarded to therapies that show promise for treating rare or serious conditions with limited existing treatment options. These designations can provide benefits such as closer collaboration with regulators, potential eligibility for expedited review pathways, and additional development incentives — all of which can help accelerate the path toward patients who need new options.

Moving into Phase 2 testing represents an important step in validating earlier research suggesting that Lacripep may help promote corneal surface repair using a naturally inspired mechanism rather than more invasive interventions. If the upcoming trial continues to demonstrate encouraging safety and efficacy signals, it could represent a meaningful advance for patients living with neurotrophic keratitis, a condition that currently has few targeted treatment options.

The progress of Lacripep also reflects the broader promise of peptide-based therapeutics in ophthalmology, where naturally derived molecules are increasingly being explored for their ability to support tissue repair with a favorable safety profile. As TearSolutions moves forward with this next phase of testing, the eye care community will be watching closely for results that could expand treatment possibilities for this challenging condition.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis – Ophthalmology Times Europe